Targeting Plasmodium PI(4)K to eliminate malaria

• Main Authors: Case W. McNamara, Marcus C.S. Lee, Chek Shik Lim, Siau Hoi Lim, Jason Roland, Advait Nagle, Oliver Simon, Bryan K.S. Yeung, Arnab K. Chatterjee, Susan L. McCormack, Micah J. Manary, Anne Marie Zeeman, Koen J. Dechering, T. R.Santha Kumar, Philipp P. Henrich, Kerstin Gagaring, Maureen Ibanez, Nobutaka Kato, Kelli L. Kuhen, Christoph Fischli, Matthias Rottmann, David M. Plouffe, Badry Bursulaya, Stephan Meister, Lucia Rameh, Joerg Trappe, Dorothea Haasen, Martijn Timmerman, Robert W. Sauerwein, Rossarin Suwanarusk, Bruce Russell, Laurent Renia, Francois Nosten, David C. Tully, Clemens H.M. Kocken, Richard J. Glynne, Christophe Bodenreider, David A. Fidock, Thierry T. Diagana, Elizabeth A. Winzeler
• Other Authors: The Genomics Institute of the Novartis Research Foundation
• Format: Article
• Published: 2018
• Subjects: Multidisciplinary
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/32815
• Institution: Mahidol University

Achieving the goal of malaria elimination will depend on targeting Plasmodium pathways essential across all life stages. Here we identify a lipid kinase, phosphatidylinositol-4-OH kinase (PI(4)K), as the target of imidazopyrazines, a new antimalarial compound class that inhibits the intracellular de...